Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report.

Atopic dermatitis (AD) is a common inflammatory skin disease, which negatively impacts the individual's quality of life (QoL). In particular, moderate-to-severe AD is frequently difficult to treat. We report a case involving a 40-year-old male who has suffered from AD since early childhood and who also had co-morbid seasonal allergic rhinitis. In June 2021, we initiated treatment with the fully human IgG4 monoclonal antibody tralokinumab that specifically targets IL-13 and the patient has been followed for 38 weeks. During this time period, he received a booster vaccination for COVID-19 (week 18) and developed the disease in April 2022 (both with minimal impact). Tralokinumab treatment reduced AD symptoms, was well tolerated and improved QoL scores, and the patient reported that he was very satisfied with the treatment.

Informations de copyright

© 2022 Moennig and Traidl.

Déclaration de conflit d'intérêts

Dr Eva Moennig reports personal fees from Leo Pharma, during the conduct of the study. Dr Stephan Traidl reports personal fees from Leo Pharma, during the conduct of the study; personal fees from Janssen, Sanofi, LaRoche-Posay, Novartis, and Lilly Pharma, outside the submitted work. The authors report no other conflicts of interest in this work.